Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

103.91 +0.94 (+0.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
One World Trade Center to be lit up in green in observance of Mental Health Month 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
NASDAQ: AXSM Shareholder Notice: Investigation over Potential Wrongdoing at Axsome Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 04/27/2023 -- Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Long Term Investor Alert: Lawsuit Against Directors Filed
San Diego, CA -- (SBWIRE) -- 02/17/2023 -- An investor in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) filed a lawsuit against certain directors of Axsome Therapeutics, Inc. over alleged breaches... 
Via SBWire
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback